10-Q · May 20, 2026
Scilex Holding Company experienced significant financial setbacks in Q1 2026, reporting revenue of $8.6 million, falling short of $5 million in the same quarter last year and a staggering EPS of -$45.7 million…
Earnings analysis · 10-Q
SCLX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q text does not include the current-quarter income statement, balance-sheet detail beyond liquidity disclosures, or cash-flow statement, so revenue, margins, EPS and free cash flow cannot be assessed for…
Read full summary
The provided 10-Q text does not include the current-quarter income statement, balance-sheet detail beyond liquidity disclosures, or cash-flow statement, so revenue, margins, EPS and free cash flow cannot be assessed for Q2 2026. Liquidity is severely constrained, with approximately $0.6 million of cash at June 30, 2026, accumulated deficit of $1,078.6 million and six-month net loss of $160.6 million. Near-term financing and debt-servicing risk is material, including $29.5 million owed under the Oramed Note and a stated need for financing to fund operations for the next 12 months.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Cash resources remain extremely limited
Management reported cash and cash equivalents of approximately $0.6 million as of June 30, 2026, alongside an accumulated deficit of $1,078.6 million.
-
Management expects continued substantial losses
The company stated that it expects to continue incurring significant losses for the foreseeable future, with six-month 2026 net losses of $160.6 million versus $70.1 million for six-month 2025.
-
Three-product commercialization focus
Management identified ZTlido, GLOPERBA and ELYXYB as its key commercialization programs and said GLOPERBA and ELYXYB remain in the early stages of commercialization.
-
Potential strategic transaction under review
The filing disclosed a proposed PHOE Acquisition involving 100,000,000 newly issued Phoenix Asia shares valued by the parties at $1.0 billion; ACEA Therapeutics is expected to own approximately 82% of Phoenix Asia after closing.
What to watch
-
Substantial doubt over going concern
The going-concern risk intensified: the company had approximately $0.6 million of cash as of June 30, 2026, negative working capital and stated that additional financing is needed to fund current operations for the next 12 months.
-
Near-term debt maturity and default exposure
Debt-refinancing and default risk increased because the Oramed Note had outstanding principal, accrued interest and fees of $29.5 million as of June 30, 2026, with the due date extended to September 30, 2026. An event of default could require repayment at 125% of principal, plus accrued interest and other amounts.
-
Multiple uncompleted strategic transactions
New transaction-completion risks were added for the PHOE Acquisition and other proposed deals. The term sheets include a proposed $120.0 million Datavault cash contribution, a $50.0 million purchase of 837 Bitcoin and two proposed $100.0 million investments, but no definitive agreements had been entered into as of the filing date.
Management's outlook
No quantitative revenue or EPS guidance was disclosed in the provided 10-Q text; outlook was limited to financing needs, continued losses and commercialization plans.
Earlier filings 4
10-K · April 10, 2026
Scilex positions itself as a revenue-generating, non-opioid pain-management company with three commercial products (ZTlido, ELYXYB, GLOPERBA) and late-stage candidates (SEMDEXA, SP-103, SP-104). The company is expanding…
10-Q · November 14, 2025
Scilex reported third-quarter revenue of $10,560,000 and a GAAP net loss of $257,820,000 (three months ended September 30, 2025), driven by a large increase in selling, general and administrative expense and…
10-Q · August 13, 2025
Scilex reported net revenue of $9,896 (in thousands) for Q2 ended June 30, 2025, up from $5,004 (in thousands) in Q1 but down from $16,370 (in thousands) in prior‑year Q2. The company recorded a net loss per common…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.